BioCryst Pharmaceuticals
BCRX
BCRX
133 hedge funds and large institutions have $826M invested in BioCryst Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 52 increasing their positions, 25 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding
Funds holding: →
1% more capital invested
Capital invested by funds: $817M → $826M (+$8.86M)
0.25% less ownership
Funds ownership: 92.34% → 92.09% (-0.25%)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Holders
133
Holding in Top 10
4
Calls
$8.87M
Puts
$5.79M
Top Buyers
| 1 | +$12.1M | |
| 2 | +$6.09M | |
| 3 | +$5.8M | |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.87M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$3.14M |
Top Sellers
| 1 | -$16.3M | |
| 2 | -$13.6M | |
| 3 | -$8.45M | |
| 4 |
Jennison Associates
New York
|
-$5.68M |
| 5 |
DM
Deerfield Management
New York
|
-$3.04M |